The FDA gives Teleflex clearance to market more models of its Arrow GPSCath balloon dilatation device suite, which the company picked up during the 2012 Hotspur buyout.
Teleflex (NYSE:TFX) won FDA clearance for expanded sizes and uses of its Arrow GPSCath Balloon Dilatation catheter, a device the company picked up during the 2012 buyout of Hotspur Technologies.
The FDA win lets Teleflex sell the catheter in new 80 cm lengths and in a higher burst pressure rating. The Limerick, Pa.-based device company calls the Arrow GPS a “dual-function” balloon catheter because of its ability to widen arteries while injecting fluids.
![An illustration showing the Edwards Lifesciences Sapien M3 transcatheter mitral valve replacement (TMVR) system's valve being placed in the heart. [Image courtesy of Edwards Lifesciences]](https://www.medicaldesignandoutsourcing.com/wp-content/uploads/2025/04/Edwards-Lifesciences-Sapien-M3-TMVR-valve-delivery-268x170.jpg)
